Zacks Research Issues Optimistic Estimate for JAZZ Earnings

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) – Zacks Research upped their Q1 2025 earnings estimates for shares of Jazz Pharmaceuticals in a research note issued on Tuesday, April 29th. Zacks Research analyst S. Ganoria now anticipates that the specialty pharmaceutical company will earn $3.52 per share for the quarter, up from their prior forecast of $3.51. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.96 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals’ Q2 2026 earnings at $4.75 EPS, Q3 2026 earnings at $5.78 EPS, Q4 2026 earnings at $5.85 EPS, FY2026 earnings at $19.49 EPS, Q1 2027 earnings at $3.34 EPS and FY2027 earnings at $20.54 EPS.

JAZZ has been the subject of a number of other research reports. Morgan Stanley reiterated an “overweight” rating and set a $183.00 target price (up previously from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. Needham & Company LLC reiterated a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, April 10th. Barclays reiterated an “overweight” rating and set a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Cantor Fitzgerald cut Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and boosted their target price for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Finally, Piper Sandler restated an “overweight” rating and issued a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $187.71.

Jazz Pharmaceuticals Stock Up 0.2 %

Shares of NASDAQ:JAZZ opened at $117.18 on Thursday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals has a 1 year low of $95.49 and a 1 year high of $148.06. The stock has a market capitalization of $7.22 billion, a P/E ratio of 16.50, a PEG ratio of 1.04 and a beta of 0.42. The stock has a 50-day simple moving average of $123.02 and a 200-day simple moving average of $122.40.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. IFP Advisors Inc acquired a new position in Jazz Pharmaceuticals during the 4th quarter worth $25,000. Quadrant Capital Group LLC lifted its position in shares of Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after buying an additional 101 shares during the last quarter. Elequin Capital LP lifted its position in shares of Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock worth $26,000 after buying an additional 183 shares during the last quarter. CoreFirst Bank & Trust bought a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth about $28,000. Finally, Allianz SE bought a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth about $29,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total transaction of $183,465.00. Following the completion of the transaction, the chief executive officer now directly owns 439,744 shares of the company’s stock, valued at $53,785,088.64. This trade represents a 0.34 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Robert Iannone sold 7,080 shares of the firm’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $138.60, for a total transaction of $981,288.00. Following the transaction, the chief marketing officer now directly owns 82,024 shares of the company’s stock, valued at approximately $11,368,526.40. This represents a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock valued at $4,023,305 over the last ninety days. Corporate insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.